Cerus (CERS) Q1 2026 Earnings Transcript

Cerus reported Q1 2026 product revenue of $53.7 million, up 24% year over year, and raised full-year 2026 product revenue guidance to $227 million-$231 million while lifting IFC guidance to $22 million-$24 million. Gross margin fell to 52% from 58.8% amid inflation, FX, and tariffs, but adjusted EBITDA remained positive at $4 million for the eighth straight quarter and the net loss narrowed to $1.6 million. Management also highlighted key upcoming catalysts, including the INT 100 PMA submission, the INT 200 U.S. launch in 2027, and RBC program milestones with a Q4 readout and potential CE Mark timing in 1H 2027.

Analysis

CERS is moving from a “proof of demand” story to a “proof of operating leverage” story. The key incremental signal is not just raised revenue, but that growth is being pulled by two distinct channels: a maturing platelet franchise that is gaining distribution access, and IFC, which remains in an early share-grab phase with a large addressable market. That combination matters because the second leg has a structurally better margin profile once kit-based sales fully displace finished-therapeutic sales, so the revenue mix itself should become a margin tailwind over the next 2-4 quarters.

The market is likely underestimating how much of the 2026 setup is self-reinforcing. BCA access should expand customer count first, then hospital utilization second, and only then show up as repeat consumables pull-through; that lag means the Q1 print may be the start of a multi-quarter acceleration rather than a one-off beat. Separately, the French renewal and international device rollout reduce concentration risk, but they also create a subtle currency hedge problem: as international mix rises, reported growth can look better or worse purely on FX, which increases the odds of volatile quarterly reactions even if underlying demand stays intact.

The main bear case is gross margin compression staying sticky longer than management expects. Inflation, tariffs, and freight are not transitory for a small-cap medtech with global shipping exposure, and if revenue growth decelerates before mix improvement arrives, EBITDA leverage could flatten for 1-2 quarters. The bigger catalyst stack is late-2026: RBC readout, INT 100 PMA submission, and continued BCA rollout. If any one of those slips, the stock likely de-rates because the current setup assumes a clean regulatory and commercial cadence into 2027.

Key Decisions for Investors

• Long CERS into the next 1-2 quarters on pullbacks, with a 6-9 month horizon: the setup is favorable if revenue continues compounding above 10% and IFC mix keeps expanding. Risk/reward is attractive while the market prices it as a single-product medtech rather than a multi-catalyst platform.
• Buy CERS calls or call spreads targeting the 2026 RBC readout window (Q4): upside is convex if the readout de-risks a 2027 Europe/US commercial path, but premium should be sized modestly because regulatory timing remains binary.
• Pair trade: long CERS / short a higher-quality medtech name with less operating leverage (e.g., BAX) over 3-6 months. The thesis is that CERS has superior top-line torque and multiple expansion potential if execution holds, while broader medtech may lag in an easing-growth tape.
• Take profits into strength if CERS re-rates quickly on the guidance raise: the stock likely trades ahead of itself on the first few quarters of BCA-driven momentum, but the cleaner entry is after any margin-driven pullback in the next earnings cycle.
• If you want lower event risk, wait for confirmation that gross margin stabilizes above the low-50s before adding size. That would validate that revenue growth is starting to outpace tariff/freight drag and make the EBITDA inflection more durable.